CLLD8/SETDB2 Antibody (Center V514) Blocking peptide
€363.00
In stock
SKU
AC-BP1075b
Background:
Proteins that contain a SET domain, such as SETDB2, modulate gene expression epigenetically through histone H3 methylation. SETDB2 is likely a histone H3 methyltransferase, as it contains both the active site and flanking cysteine residues required for catalytic activity.
Other Names:
Histone-lysine N-methyltransferase SETDB2, Chronic lymphocytic leukemia deletion region gene 8 protein, Lysine N-methyltransferase 1F, SET domain bifurcated 2, SETDB2, C13orf4, CLLD8, KMT1F
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP1075b was selected from the Center region of human SETDB2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: SETDB2
Gene ID: 83852
Primary Accession: Q96T68
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
Proteins that contain a SET domain, such as SETDB2, modulate gene expression epigenetically through histone H3 methylation. SETDB2 is likely a histone H3 methyltransferase, as it contains both the active site and flanking cysteine residues required for catalytic activity.
Other Names:
Histone-lysine N-methyltransferase SETDB2, Chronic lymphocytic leukemia deletion region gene 8 protein, Lysine N-methyltransferase 1F, SET domain bifurcated 2, SETDB2, C13orf4, CLLD8, KMT1F
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP1075b was selected from the Center region of human SETDB2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: SETDB2
Gene ID: 83852
Primary Accession: Q96T68
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
| Is Featured? | No |
|---|
Write Your Own Review